Clinical Trials

Genervon is currently conducting a Phase 2 clinical trial evaluating GM6 for patients who have experienced an acute ischemic stroke within 18 hours. The study is still recruiting patients. This study has also received fast track designation from the FDA. Additional information can be found using the identifier NCT01221246 at clinicaltrials.gov.

A previous Phase 1 clinical study demonstrated that GM6 was safe at all doses in 32 healthy volunteers. In the randomized, placebo-controlled, single dose-escalation study healthy volunteers received .5, 1.5 and 5.0 mg/kg doses as well as three consecutive daily doses of 5.0 mg/kg of the therapeutic.

A Phase 2A study evaluating GM6 in Parkinson's patients has been completed. Additional information can be found using the identifier NCT01850381 at clinicaltrials.gov. Topline results are available in Genervon's Press Releases

A Phase 2A study evaluating GM6 in ALS patients has been completed. Additional information can be found using the identifier NCT01854294 at clinicaltrials.gov. Topline results are available in Genervon's Press Releases. A compassionate trial was also completed and reported in Genervon's Press Releases


 
Copyright © 2017 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.